

## Experts discuss future of diagnostics, med-tech on concluding day of FICCI HEAL 2021

22 October 2021 | News

**Panel discussions were held on key aspects of the healthcare ecosystem including capacity building for the next decade, future of diagnostics and med-tech industry in India**



The third and final day of the 15th edition of the FICCI HEAL 2021, on 22 October, saw panel discussions on how to bring healthcare to everybody's doorstep and the future of med-tech industry in India. Speakers focussed on the recognition received for home healthcare and the transformation to the digital care models during the pandemic.

Dr Om Manchanda, MD, Dr Lal PathLabs shared that the Indian market is larger as compared to many other countries and there is a huge potential for organised players and a shift from unorganised to organised is required."

Travis Monke, GM-APAC, Abbott Molecular Diagnostics said, "The introduction of fast, reliable, molecular and rapid antigen tests illustrates the benefit of decentralised technologies at the point of care."

Dr Shravan Subramanyam, FICCI Medical Devices Committee and President & CEO, GE Healthcare South Asia said, "The mandate from our government to be self-reliant is very critical, and med-tech sector which faced many challenges during the pandemic, has benefited quite a lot through production linked incentives and various other schemes."

Madan Krishnan, VP and MD, India Medtronic talked about the need for a single-window clearance system so that there is an ease of expansion of health infrastructure.

Kaivaan Movdawalla, Partner- Healthcare, EY shared, "India needs to add nine lakh more beds over the next decade to serve the UHC agenda over the next decade. It is imperative to ensure equitable generation and distribution of this capacity in under-served districts through targeted incentives and viability gap funding."